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The immunogenicity of alphavirus replicon vaccines is determined by many factors including the level of
antigen expression and induction of innate immune responses. Characterized attenuated alphavirus
mutants contain changes to the genomic 5′ UTR and mutations that result in altered non-structural
protein cleavage timing leading to altered levels of antigen expression and interferon (IFN) induction. In
an attempt to create more potent replicon vaccines, we engineered a panel of Venezuelan equine
encephalitis-Sindbis virus chimeric replicons that contained these attenuating mutations. Modiﬁed
replicons were ranked for antigen expression and IFN induction levels in cell culture and then evaluated
in mice. The results of these studies showed that differences in antigen production and IFN induction
in vitro did not correlate with large changes in immunogenicity in vivo. These ﬁndings indicate that the
complex interactions between innate immune response and the replicon′s ability to express antigen
complicate rational design of more potent alphavirus replicons.
& 2013 Elsevier Inc. All rights reserved.Introduction
Vaccine vectors based on alphaviruses have proven to be potent
inducers of antigen-speciﬁc immunity (Atkins et al., 2008; Geall
et al., 2012; Leitner et al., 2003; Rayner et al., 2002; Ulmer et al.,
2012). These vaccines are based on derivatives of the alphavirus
genome, which is a message-sense, single-stranded RNA with a 7-
methyl-G cap at their 5′ terminus and a poly(A)-tail at their 3′
terminus (Strauss and Strauss, 1994). Alphavirus genomes encode
four non-structural proteins, nsP1–4, which are translated directly
from the genomic RNA and interact with host factors to form
replicative enzyme complexes (Lemm and Rice, 1993; Lemm et al.,
1994). These replicative complexes synthesize the negative-strand
RNA intermediates, new viral genomes and the subgenomic RNA,
which encodes for the structural proteins necessary for viral
particles assembly (Strauss and Strauss, 1994).
Alphavirus vaccine vectors have been developed from viral
genomes by replacing the structural protein genes with hetero-
logous genes. The resulting RNAs, called replicons, are capable of
directing their own replication and express high levels of the
heterologous gene when they are introduced into the cytoplasm of
host cells. Since these replicons lack the alphavirus structuralll rights reserved.
s Vaccines and Diagnostics,
77 5346.
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ostics Srl, Via Fiorentina 1,protein genes, they are incapable of forming virions and spreading
to adjacent cells. However, replicons can be efﬁciently packaged
into virus replicon particles (VRPs) by introducing them into cells
where the structural proteins are provided in trans (Perri et al.,
2003; Pushko et al., 1997).
Several features of VRPs make them attractive candidates for
use as vaccine vectors, ﬁrst of all their ability to stimulate strong
immune responses against the encoded antigen. The heterologous
gene is expressed at high levels (Xiong et al., 1989) and can be
delivered to a variety of cell types, including antigen-presenting
cells (Gardner et al., 2000; MacDonald and Johnston, 2000;
Nishimoto et al., 2007). The in vivo vector ampliﬁcation, through
double-stranded RNA intermediates, stimulates aspects of innate
immunity, such as activation of the type I interferon (IFN) (Leitner
et al., 2003). Furthermore, the production of antigen in vivo in a
manner that mimics production of antigens by viral pathogens,
elicits both humoral and cellular immune responses (Leitner et al.,
2003; Perri et al., 2003) that have been shown to confer protection
against viral challenge in many animal models (Ryman et al.,
2002). The induction of neutralizing antibodies and poly-
functional CD4+ and CD8+ T cell responses has been demon-
strated in humans in a clinical trial performed with VRPs encoding
cytomegalovirus gB and pp65/IE1 proteins (Bernstein et al., 2009).
The efﬁcient immune responses elicited by alphavirus replicons
has been attributed both to the production of high levels of
correctly processed heterologous proteins (Liljestrom and Garoff,
1991) and to the activation of innate responses. Upon alphavirus
infection, the double-strand RNA (dsRNA) produced by replication
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receptors, referred to as pattern recognition receptors, that are
broadly expressed by immune and non-immune cells and include
the RNA sensors PKR, MDA-5, and/or RIG-I. The signals coming
from the stimulated receptors activate IRF-3/7-dependent signal-
ing pathways that induce the IFN-mediated antiviral response
(Gitlin et al., 2006; Hidmark et al., 2006; Pichlmair et al., 2009;
Ryman et al., 2002). IFN signaling is not only a key component of
the innate immune response to viral infections (van den Broek
et al., 1995), it also plays an important role in potentiating the
adaptive immune responses (Fink et al., 2006) and consistent with
this latter activity, alphavirus replicon particles have been shown
to adjuvant adaptive immune responses of co-administered pro-
teins (Hidmark et al., 2006; Thompson et al., 2006; Thompson
et al., 2008a). However, the relative importance of the levels of the
expression of replicon-encoded antigens and activation of IFN
response by the replicon (which can both help to control replicon
replication and adjuvant responses to the heterologous antigen) in
the adaptive immune responses induced by the replicon-encoded
antigens is unclear.
The viral genome sequences involved in the regulation of the
alphavirus RNA replication, subgenomic RNA transcription, and
IFN induction have been described for multiple members of the
alphavirus family. In the case of the best-studied member of the
encephalitic alphaviruses, Venezuelan equine encephalitis virus
(VEEV), viral pathogenesis strongly depends on the sequence of
the RNA promoter, as demonstrated by studies showing that the
3rd base of the positive-sense viral genome ((+) RNA) controls
viral attenuation (Kinney et al., 1993). This mutation, correspond-
ing to a G3-A change (G3A), is found near the end of a 44-base
untranslated region found at the 5′ end of the of the viral genome
(5′ UTR), which is predicted to form part of a complex secondary
structure (Kulasegaran-Shylini et al., 2009a)). The 5′ UTR (more
precisely, its complement in the negative-strand of the viral
genome () RNA) functions as the core promoter for positive-
strand genome synthesis (Frolov et al., 2001) and promotes
efﬁcient viral genome replication (Gorchakov et al., 2003). As
indicated above, the sequence of the 5′ UTR in VEEV plays a
signiﬁcant role in virus pathogenesis, with the G3A mutation,
found in the attenuated TC-83 strain of this virus, as one of the
major determinants of its less pathogenic phenotype (Kinney et al.,
1993; White et al., 2001). Interestingly, the G3A mutation
increases transcription of the viral genome, down-regulates tran-
scription of the subgenomic RNA, and results in a decrease in the
molar ratio of subgenomic to genomic RNA synthesis
(Kulasegaran-Shylini et al., 2009a, 2009b).
In the case of the arthralgic alphaviruses, the cleavage site
between nsP1 and nsP2 proteins appears to be a major determi-
nant of viral pathogenesis. A single amino acid mutation of the P3
position of the nsP1/nsP2 cleavage site for two distant related
alphaviruses, SINV and Ross River Virus (RRV), resulted in
enhanced type I IFN induction and virulence attenuation in
comparison to the wild-type (wt) viruses (Cruz et al., 2010). The
wt amino acid in the P3 position of the nsP1/nsP2 cleavage
recognition domain (nsP1 position 538 in SINV and 532 in RRV)
has been shown to be both necessary and sufﬁcient for rapid and
efﬁcient inhibition of STAT1 activation (Simmons et al., 2010).
When the residue at position P3 is mutated in SINV, the virus is
rendered unable to counteract the Jak/STAT signaling necessary for
IFN activation of cells, and consequently these mutant viruses are
highly attenuated (Simmons et al., 2010).
The aim of this study was to construct alphavirus-based
replicon vaccines that were capable of eliciting improved immune
responses. We looked to known attenuated viruses as a guide for
determining how to alter the interaction between virus and
immune system. There are many attenuated alphaviruses thathave been characterized to identify the mutations and mechan-
isms responsible for their attenuation. Many of these attenuated
mutants contain changes to their 5′ UTR or non-structural coding
regions. Mutations in these regions often simultaneously alter
several aspects of the virus lifecycle including replication, protein
expression, and virus/host interactions. Due to these pleiotropic
effects it is difﬁcult to identify a single phenotypic change that
correlates with attenuation but all of the mutant viruses do have
an altered interaction with the host immune response and they
could possibly lead to altered immune reponses in the context of
an alphavirus-based replicon. Therefore we selected a sampling of
the known attenuating mutations and built them into our existing
replicons to then empirically test them for improved immune
responses. We used antigen expression levels and IFN production
as tools to characterize the mutant replicons in vitro before testing
them in vivo. The replicon we used is derived from VEEV but
contains regions from SINV, as the 3′ UTR region. The structural
proteins are derived from SINV and to ensure efﬁcient packaging
of VEEV replicons into SINV virions, the SINV packaging signal was
introduced into the nsp3 region of the VEEV replicon. The result-
ing VRPs are similar to VEEV VRPs in production yields from
electroporated BHK cells, RNA replication and antigen expression
in infected cells, interferon resistance, and immunogenicity in vivo
(Perri et al., 2003).Results
Effect of 5′UTR mutations on predicted RNA secondary structures
and speciﬁc infectivity of the VEEV/SINV replicons
Since the G3A mutation found in TC-83 viral genome is one of
the primary determinants of its less pathogenic phenotype, and
this attenuation is associated with changes in type I IFN induction,
we targeted this site for analysis in our VEEV/SINV replicon. In
silico folding of the 5′ ends of the genomes of TC-83 and its
parental genome (the Trinidad Donkey strain of VEEV, which is
found in the 5′ end of our VEEV/SINV genome) revealed that this
change has dramatic effects on the predicted secondary structures
(compare G3 and G3A in Fig. 1A) (Kulasegaran-Shylini et al.,
2009a; Kulasegaran-Shylini et al., 2009b). In the case of the wt
genome (G3), the predicted () RNA structure mirrors the stem-
loop structure of the positive strand (originally reported by
Kulasegaran-Shylini 2009b) (Fig. 1A). Within the 5′ UTR, mutations
in position 3 that have been shown to be responsible for the
attenuation of vaccine strain TC-83 have a profound effect on the
predicted secondary structure of the positive strand (Fig. 1A).
Furthermore, this mutation leads to predictions of multiple ()
RNA structures of similar overall free energy suggesting a structure
that is more dynamic than that predicted for the parental virus.
The most stable predicted conformation is characterized by a
longer stem, with two bulges, and a smaller terminal loop
(Kulasegaran-Shylini et al., 2009b). To determine if this mutation
would also affect our VEEV/SINV replicon (Fig. 1B), we created a
G3A variant by using site-speciﬁc mutagenesis of the parental G3
replicon and compared infectivity of derivatives expressing either
green ﬂuorescent protein (GFP) or secreted alkaline phosphatase
(SEAP) in BHK-V cells. Transfection efﬁciency of in-vitro synthe-
tized RNAs was measured using antigen speciﬁc staining by
cytoﬂuorimetric (GFP-expressing cells) and colorimetric (SEAP-
expressing cells) analysis. The G3A replicon was characterized by
more than 2-fold increase in speciﬁc infectivity, measured as a
number of GFP- or SEAP-positive cells per ng of transfected RNA,
over the wt G3 backbone (Fig. 1C). We also observed a slight
decrease in antigen expression (data not shown), that, according to
Fig. 1. Effects of 5′ UTR mutations on predicted RNA secondary structures and on VEEV/SINV replicons infectivity. (A) Computer-prediction (M-fold) (Jaeger et al., 1989) of
secondary structures of the 5′ termini variants having mutations in position 3, 24 and/or 30, showed a variety of secondary structures both on (+) and () RNA strands. The
predicted foldings of the wt sequence (G3) are shown. The overall free energy (ΔG, expressed in kcal/mol) is indicated. When multiple structures were predicted for the same
sequence, we selected the one having the lowest free energy. (B) Schematic representation of the VEEV/SINV replicon used to test the mutations from (A). The arrow
indicates the position of the subgenomic promoter. VEEV 5′ UTR: VEEV wt 5′ UTR sequence having a G in position 3 (G3 wt control); GOI: gene of interest/antigen; nsPs: non-
structural proteins; light gray regions indicate sequences from SINV. (C) Analysis of the effect of the 5′ UTR mutations on VEEV/SINV replicon speciﬁc infectivity. The
mutations from (A) were inserted in the G3 genome by PCR-based mutagenesis. The PCR products were used as template for in vitro transcription and capping. Equal number
of BHK-V cells was transfected with 109 copies of RNA carrying the indicated 5′ UTR mutation and expressing GFP or SEAP reporter gene. The number of positive cells was
evaluated 12 h post-transfection. The shown values are relative to the G3A-speciﬁc infectivity.
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of the G3A-speciﬁc lower subgenomic RNA transcription.
In order to ﬁnd new genome structures that might alter IFN
induction without changes in antigen expression level, we used
the data from Kulasegaran-Shylini et al. (2009b), and in silico
analyses (Jaeger et al., 1989) to test the potential of different point
mutations to produce structures in the (+) and () RNA strands
that mimicked those found on the G3 (wt) and G3A (TC-83)
genomes. Our overall strategy was to select mutations having an
A in position 3, since the G3A mutation was associated with higher
in vitro speciﬁc infectivity, and a folding resembling the conforma-
tion of the G3 or G3A on the () RNA, as this is the region that acts
as a promoter for the synthesis of the (+) RNA. Included in these
analyses was the G3A-C24U structure that was previously
described by Kulasegaran-Shylini et al. (2009a). This mutant is
characterized by the TC-83-like G3A mutation and by a predicted
secondary structure that is identical to the wt G3 5′ UTR on both
the (+) and () RNA strands. To test the importance of the single-
strand RNA in the 3′ terminus of the () RNA we predicted the
secondary structure of 5′UTRs mutated in position 3 and in
compensatory positions using in silico tools. Among the variety
of possible combinations, we identiﬁed and selected the G3A-
A30C and G3A-A30G sequences (Fig. 1A), whose predicted struc-
tures on the () RNA are identical to the G3A one, except for the
absence or the presence of the single-strand tail, respectively.
To control and to evaluate the contribution of the G3A muta-
tion on the selected 5′UTRs mutants, we in silico tested the effectof the selected mutations in position 24 and 30 in the G3 (wt)
genome, obtaining the C24U, A30C and A30G predicted structures
(Fig. 1A). The computer-predicted secondary structures of the (+)
and () RNA strands of the ﬁnal panel of mutants selected for
further analysis are shown in Fig. 1A.
To test the effect of these 5′UTR modiﬁcations on genome
replication and antigen expression, the selected mutations were
transferred to the VEEV/SINV replicons expressing GFP or SEAP
and in vitro transcribed RNAs were transfected into BHK-V cells.
The results of these studies are shown in Fig. 1C, where the data
are standardized to the speciﬁc infectivity of the G3A replicon.
These data suggested that the major determinant of speciﬁc
infectivity is the nucleotide sequence at position #3. All the
mutants having a G3A mutation had the same phenotype as the
G3A replicon, whereas all of the mutants with the wt G3 showed
lower speciﬁc infectivity, and the presence of other mutations,
which were predicted to alter the secondary structures in one or
both strands, had no detectable effect on speciﬁc infectivity.
Effect of 5′UTR mutations on expression levels, activation of innate
immune response, and immunogenicity of VEEV/SINV replicons
To further dissect the role of sequence and predicted secondary
structures of the terminal regions of the (+) and () RNA on the
replicon phenotype, the G3, G3A, G3A-C24U, and G3A-A30C
mutants were selected for further characterization. The G3A-
C24U represents an interesting alternative to the current replicon
Fig. 2. Effect of 5′ UTR mutations on expression levels and activation of innate immune response of VEEV/SINV replicons. Antigen expression levels in BHK-V (A) and L929
(B) cells infected with an MOI of 1 with the G3A, G3A-A30C, G3A-C24U and G3 VEEV/SINV VRPs expressing SEAP or RSV-F antigen. Infected cells were analyzed 24 h post-
infection. The antigen levels were measured by a chemiluminescent assay (SEAP) or ELISA (RSV-F) on the collected supernatants and normalized for the number of positive
cells. (C) Interferon induction in L929 cells, infected with an MOI of 1, measured by IFN-β speciﬁc ELISA in the supernatant harvested 24 h post-infection and normalized for
the number of positive cells. Each bar represents the average of three (A, B) or two (C) different experiments. Error bars represent the standard error of the mean.
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induction with the higher antigen expression typically reported for
the G3 backbone. On the other hand the G3A-A30C, which is
missing the predicted single-strand RNA tail in the () RNA
structure, could be helpful in deﬁning the role of the single-
strand tail on the promoter function.
To further assess the effects of these mutations in vitro and
in vivo, each replicon was packaged into VRPs by providing the
SINV capsid and envelope glycoproteins in trans from defective
helpers (Perri et al., 2003). VRP stocks were readily produced at
high titers (5–10  107 IU/ml) from all constructs, suggesting that
the changes in the 5′UTR did not have signiﬁcant effects on
genome replication or trans-ampliﬁcation of defective helper
genomes. Using these VRPs, the effect of the encoded mutations
on antigen expression levels (SEAP and soluble RSV-F) and IFN
production in vitro was determined on IFN-deﬁcient cells (BHK-V)
and IFN-competent cells (L929). In all cases, the expression of the
proteins (SEAP, RSV-F, or IFN) was standardized to the number of
replicon-positive cells in the cultures (Fig. 2). The tested VRPs
produced similar levels of protein, independently from the 5′UTR
sequence (Fig. 2A, B) and predicted folding. There was a difference
in the amount of antigen secreted by the two cell lines, with a
lower expression in L929 cells. This reduction was more pro-
nounced in the case of soluble RSV-F, whose expression was more
reduced in L929 cells when compared to BHK-V cells (Fig. 2B). To
examine the effect of the 5′UTR sequence and predicted secondary
structures on innate immune activation, the 5′UTR mutations were
examined for their effect on the ability of VEEV/SINV VRP to
induce IFN-β. The production of murine IFN-β in vitro was
measured in the supernatants of L929, 24 h after infection with
either the G3 or G3A-derived VRP, and normalized to the number
of antigen expressing cells. As shown in Fig. 2C, cells infected with
the G3A replicon produced approximately 2-fold more IFN than
the wt G3 replicon. This conﬁrmed that in our chimeric replicon
the single G3A change in the 5′ UTR causes an increase in the
induction of IFN-induced antiviral response. The higher IFN
activation observed in the presence of the G3A TC-83-like
sequence could explain the higher sensitivity of TC-83 virus to
the antiviral actions of IFN-α/β described by White et al. (2001).
IFN levels found in the supernatants of L929 cells infected with the
G3A-C24U VRP showed similar levels of IFN production to those
detected in L929 cells infected with G3 VRP, whereas the cells
infected with G3A-A30C VRPs displayed an IFN response similar,
or higher when RSV-F is encoded, to that detected in cells infected
with G3A VRPs. This phenotype was independent of the antigen
tested. The different response given by G3A-C24U and G3A-A30C
is likely to be dependent on the different predicted folding of
these RNAs.Based on computer predictions, the only difference between
the two mutants, carrying the same TC-83-like G3A sequence, is
the secondary structure of the 5′ UTR. The presence of a less stable
structure, with multiple bulges and stems, predicted in the G3A
and G3A-A30C () RNA may be better recognized by the host
nucleic acid-sensing machinery that triggers the activation of type
I IFN response.
We next examined the effect of 5′ UTR modiﬁcations on
antigen production in vivo, by following the levels of SEAP in the
sera of mice infected with 106 IU of VRPs carrying the wt and
mutant VEEV/SINV replicons. At 24 hours post-injection the G3
replicon produced levels of SEAP that were signiﬁcantly higher
than the G3A replicon antigen production (p¼0.019 as determined
by a 2-tailed t-test), and this pattern was maintained at 3 days
post-inoculation. By 7 days post-inoculation, no differences were
detectable. The G3A-C24U and G3A-A30C expression levels were
in between the G3A and G3 replicons, with G3A-C24U expression
pattern closer to the wt G3 5′ UTR phenotype (Fig. 3A). Interest-
ingly, these in vivo phenotypes conﬁrmed the presence of two
classes of mutants, according to their predicted folding. This was in
agreement with what we observed in vitro, and much clearer
especially in terms of antigen expression.
To assess the immunogenicity of our panel of mutant replicons,
mice were immunized with 106 IU of the indicated VRP on days
0 and 21. Sera were collected 3 weeks after the 1st vaccination
(3wp1) and 2 weeks after the 2nd vaccination (2wp2) and tested
for F-speciﬁc IgG titers (Fig. 3B). F-speciﬁc splenic T cell responses
were measured when the animals were euthanized at 2wp2
(Fig. 3C). G3A and G3 VRPs both elicited a strong, F-speciﬁc serum
IgG response in mice, both after the ﬁrst and second vaccination,
with responses detected in 100% of the treated mice. The F-speciﬁc
responses detected in the sera of mice inoculated with the VRP
carrying the G3A-C24U replicon appeared to elicit stronger
responses than those detected in sera from mice inoculated with
VRPs carrying the G3A replicon following both vaccinations, but
this difference was small (p¼0.045 at 2wp2 as determined by a
2-tailed t-test ). The positive effect on antibody induction of the
G3A-C24U replicon (Fig. 3B) could be due to the combination of
the slight increase in antigen expression, typical of the G3-like
replicon structure at early times post-inoculation (Fig. 3A), and/or
the increased speciﬁc infectivity conferred by the G3A mutation
(Fig. 3C). However, when we applied Kruskal–Wallis test and Dunn
′s post test to account for multiple comparisons none of the
differences in antibody titers elicited by the G3A-C24U, G3A and
G3 VRPs were statistically signiﬁcant. F-speciﬁc responses
detected in the sera of mice inoculated with VRPs carrying the
G3A-A30C replicon appeared to be weaker than those detected in
sera frommice inoculated with VRPs carrying either the G3 or G3A
Fig. 3. Effect of 5′ UTR mutations on in vivo antigen expression and immunogenicity of VEEV/SINV replicons. (A) The indicated replicons expressing SEAP were packaged as
VRP and injected in BALB/c mice (ﬁve per group) at 106 IU/mouse. SEAP expression (shown as RLU on a logarithmic scale) was measured in the sera collected at 1, 3, 7, and 14
days post-injection as described in Material and Methods. Average of SEAP expression from ﬁve mice/group is represented for each time point and each tested replicon. Error
bars indicate the standard deviation. The dashed line indicates the amount of SEAP measured in the sera from mice inoculated with PBS. (B, C) To look at immunogenicity of
the 5′ UTR modiﬁed replicons, BALB/c mice (ﬁve mice per group) were injected with the indicated VRP (106 IU/mouse) expressing RSV-F antigen. (B) RSV-F-speciﬁc serum
IgG titers of BALB/c mice, after intramuscular vaccination with the indicated vaccines on days 0 and 21. Serum was collected for antibody analysis on days 21 (3wp1) and 35
(2wp2). Data are represented as titers for individual animals and the geometric mean titer for each group is shown. The dashed line indicates the limit of titer quantiﬁcation.
(C) Frequencies of RSV-F-speciﬁc cytokine-producing CD4+ or CD8+ splenic T cells of vaccinated BALB/c mice. Spleens were collected for T cell analysis on day 35 (2wp2).
Shown are average net F-speciﬁc cytokine-positive frequencies (%) of duplicate wells of one pool of ﬁve spleens per group. Error bars indicate the standard error of the mean.
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signiﬁcant only if comparing the response elicited by the G3A-
A30C VRPs to the G3 one at 3wp1 (p¼0.0231 as determined by
Kruskal–Wallis test and Dunn′s post test). The weaker response
elicited by G3A-A30C with respect to those of either G3 or G3A
VRP at 2wp2 were not statistically signiﬁcant (as determined by
Kruskal–Wallis test and Dunn′s post test).The absence of the
single-strand RNA tail in the RNA predicted structure did not alter
the promoter function.
Frequencies of F antigen-speciﬁc, cytokine-producing CD8+
and CD4+ T cells in spleens of vaccinated mice were measured
for the four modiﬁed VRPs. G3A and G3 VRPs both elicited a robust
F-speciﬁc CD8+, and moderate CD4+ T cell response, each produ-
cing the type-1 cytokines IFNγ, TNFα, and IL-2, without signiﬁcant
production of the type-2 cytokine IL-5 (Fig. 3C, D). The F-speciﬁc T
cell responses measured in the spleen of mice inoculated with the
VRP carrying the G3A-C24U replicon appeared to be more similar
to the G3 responses. On the other hand, G3A-A30C replicon
elicited levels of CD4+ and CD8+ T cell response more similar to
those elicited by the G3A replicon.
Taken together, these data suggest that the sequence of the
very 5′end of the 5′ UTR is a determinant of the immunogenicity of
alphavirus replicons and its structure plays an important role in
determining their phenotype. Both in vivo and in vitro data
showed that replicons carrying a G3A or G3 predicted folding act
differently in controlling antigen expression and type I IFN induc-
tion, even though these changes did not correlate with large
changes in immunogenicity.Effect of nsP1/2 cleavage site mutations on expression levels,
activation of innate immune response, and immunogenicity
of VEEV/SINV replicons
To further investigate the role of IFN response on replication,
expression and immunogenicity of our replicon vaccine, we
decided to modify the cleavage site between nsP1 and nsP2 coding
regions, as this site has been described as a major determinant of
viral pathogenesis in SINV and RRV (Cruz et al., 2010; Heise et al.,
2003). Modiﬁcation of the P3 position (Thr538Ile in SINV and
Ala532Val in RRV) in the cleavage site between nsP1 and nsP2
genes is responsible for an enhanced type I IFN induction and
virulence attenuation (Cruz et al., 2010).
To determine if the nsP1/nsP2 cleavage site is involved in the
properties of our vaccine replicon, we changed the P3 cleavage
position in nsP1 in our G3A VEEV/SINV replicon. The correspon-
dent P3 position in VEEV is in position 533 and encodes an
Alanine. We examined whether substitution with an Isoleucine
(A533I) or Valine (A533V) or Threonine (A533T) (Fig. 4A) would
result in a viable replicon with similar effects on IFN induction, as
seen with the SINV T538I and the RRV A532V mutants. All three
substitutions of Alanine 533 resulted in replicons that were able to
produce VRPs, although all three grew to lower titers (1.5-2 logs
lower, data not shown) than the VRPs made with the parental G3A
replicon. To evaluate the effect of these mutations on IFN response,
L929 cells were infected with VRPs carrying the G3A SEAP replicon
or derivatives carrying each of the mutations. This preliminary
study showed that all replicons induced more IFN than the
Fig. 4. Effects of nsP1/nsP2 cleavage site modiﬁcation on antigen expression and activation of innate immune response of VEEV/SINV replicons. (A) Three different VEEV/
SINV replicons were cloned starting from G3A genome by mutation of the Alanine in position 533 (P3 cleavage position) in Isoleucine, Valine or Threonine. The selected G3A-
A533I mutant was selected for further characterization. G3A and G3A-A533I VRPs were used to infect BHK-V and L929 cells with an MOI of 1. (B) Antigen expression levels
were measured 24 hours post-infection in the supernatant coming from BHK-V (B) and L929 (C) cells by a chemiluminescent assay (SEAP) or ELISA (RSV-F). The antigen
expression levels were normalized for the number of positive cells. (D) Type I IFN induction was measured in the supernatant of infected L929 cells 24 h post-infection.
(B, C, D) Each bar represents the average of three different experiments. Error bars represent the standard error of the mean. p-values were determined by 2-tailed t-tests.
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the cells infected with the A533I mutant (results not shown), so it
was selected for all further studies. We cloned the RSV-F antigen in
the A533I replicon to investigate the effects of this mutation on
replicon properties. We ﬁrst compared the antigen expression
levels in vitro of G3A and G3A-A533I mutants expressing SEAP or
RSV-F. The introduction of the A533I mutation resulted in a 2- to
5-fold decrease in antigen expression in BHKV cells (Fig. 4B), but
no difference was observed in infected IFN-competent L929 cells
(Fig. 4C). Next, we compared the ability of the parental and A533I
replicon to induce IFN responses. These studies showed a pro-
found increase in IFN response for G3A-A533I mutants indepen-
dent of the antigen expressed (Fig. 4D), but the difference was
more pronounced with replicon expressing the RSV-F protein. For
the pair of replicons expressing this antigen, the A533I mutation
resulted in a 15-fold increase in the IFN induction in L929 cells
when compared to the G3A replicon (p¼0.02 as determined by a
2-tailed t-test) (Fig. 4D). These data demonstrate that the effect of
nsP1 cleavage mutations on IFN induction by arthralgic alpha-
viruses also applies to our VEEV/SINV chimera.
To further evaluate this interesting mutation, in vivo studies
were conducted comparing the G3A and the G3A-A533I replicons.
Fig. 5A shows the studies comparing SEAP expression from mice
injected with SEAP-expressing VRP carrying the G3A and G3A
A533I mutant replicons. Interestingly, there were only modest
differences in SEAP produced from these replicons in vivo (Fig. 5A)
(p¼0.02), although the A533I replicon showed lower antigen
expression levels in vitro (in BHK), and higher levels of IFN
induction. Next, the G3A and the G3A-A533I RSV-F expressing
VRP were used to immunize 6–8 weeks old BALB/c mice. Acomparison of the outcome of vaccination using both serological
and cellular readouts (Fig. 5B, C), demonstrated that the G3A-
A533I replicon was much less immunogenic than the G3A parental
replicon, in particular after the ﬁrst vaccination (p¼0.01 at 3wp1
as determined by a 2-tailed t-test). These results are consistent
with the possibility that the high IFN induction predicted from our
in vitro studies with the G3A-A533I replicon (Fig. 4D), and the fact
that viruses carrying the G3A mutation are more sensitive to IFN
than viruses with a G3 genome (White et al., 2001), combined to
make this replicon less immunogenic.Discussion
Alphavirus replicon-based vectors hold great promise as vaccine
delivery vehicles and the VEEV/SINV chimeric replicon described in
this report is especially well suited for this purpose. While the potency
of alphavirus-derived replicon vaccines has been established in pre-
clinical and clinical studies (see Introduction), little is known regarding
the critical interplay between antigen expression and innate immune
activation which regulate replicon-induced immunity. In this report
we investigated the importance of the replicon genome sequences in
controlling the interactions with the host in order to rationally design
more potent alphavirus replicon-based vaccines.
The immune response elicited by alphavirus based vaccines is
believed to be determined by both high antigen expression
(Liljestrom and Garoff, 1991) and innate immune activation
(Hidmark et al., 2006; Thompson et al., 2008a). Various steps in
the alphavirus life cycle that are either an outcome of the needs for
efﬁcient replication and/or interactions with its hosts immune
Fig. 5. Analysis of the effects of A533I mutation on in vivo antigen expression and immunogenicity of VEEV/SINV replicons. (A) The differences observed in vitro had limited
effects in vivo. Six to eight weeks old BALB/c mice (ﬁve per group) were injected with 106 IU of the G3A or G3A-A533I VRPs. SEAP expression was measured in the sera
collected at 1, 3, 7, and 14 days post-injection as described in Material and Methods. Average of SEAP expression from ﬁve mice/group is represented for each time point and
each tested replicon. Standard deviation is represented by the error bars. The dashed line indicates the amount of SEAP measured in the sera from mice injected with PBS.
(B) RSV-F-speciﬁc serum IgG titers, after intramuscular vaccination in mice (ﬁve per group) with the indicated vaccines on days 0 and 21. Serum was collected for antibody
analysis on days 21 (3wp1) and 35 (2wp2). Data are represented as titers for individual animals and the geometric mean titer for each group. The dashed line indicates the
limit of titer quantiﬁcation. (C) Frequencies of RSV-F-speciﬁc cytokine-producing CD4+ or CD8+ splenic T cells of BALB/c mice, after intramuscular vaccination with the
indicated vectors. Spleens were collected for T cell analysis on day 35 (2wp2). Shown are average net F-speciﬁc cytokine-positive frequencies (%) of duplicate wells of one
pool of ﬁve spleens per group. Error bars indicate the standard error of the mean.
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vectors. We applied a genetic approach to analyze a subset of
mutations taken from attenuated alphaviruses that could affect
these events to try to increase the potency of our alphavirus
replicon-based vaccines. We started our analysis by mutating
sequences to change both primary and secondary structures
within the RNA promoter region of the genome. The VEEV core
promoter (5′ UTR) for the positive strand genome synthesis is an
important regulator of viral pathogenesis (Kinney et al., 1993), and
both primary sequence and secondary structure play a critical role
in its function (Kulasegaran-Shylini et al., 2009a). The VEEV TRD
genome 5′ UTR (corresponding to the sequence of the G3 replicon
used in this study) is predicted to form a stem-loop structure on
the (+) RNA strand that is mirrored on the () RNA strand.
Modiﬁcation of a single base at position 3 of this promoter, which
is found in the attenuated TC-83 vaccine strain, can dramatically
change viral pathogenesis (Kinney et al., 1993) and phenotype
(Kulasegaran-Shylini et al., 2009b). Previous work has shown that
this mutation reduces the stability of the 5′-terminal stem loop on
the (+) RNA strand and causes a similar change in the 3′end of the
() RNA strand intermediate. As a result, this mutation affects
multiple processes of the virus replication cycle, changing RNA
infectivity, and the transcription of the subgenomic RNA
(Kulasegaran-Shylini et al., 2009b).
In the present study, the TC-83-like G3A mutation was trans-
ferred to our VEEV/SINV chimeric replicon. This single G3A changein the 5′ UTR caused a decrease of antigen expression (in vivo) and
an increase in the induction of IFN-induced antiviral responses
(in vitro) with respect to the chimeric replicon carrying a wt 5′
UTR sequence. Using the data from Kulasegaran-Shylini et al.
(2009a) and in silico computer prediction of RNA secondary
structures (Jaeger et al., 1989) we selected mutations having an
A in position 3 and a folding resembling the conformation of the
G3 or G3A replicon on the () RNA strand. By comparing two set
of mutants having the G3 or G3A sequence and folding respec-
tively, it was clear that the major determinant of in vitro speciﬁc
infectivity of transfected RNA replicons was the sequence in
position 3, with all the mutants carrying the G3A mutation having
a higher speciﬁc infectivity than the G3 derived mutants. Based on
the available data (Kulasegaran-Shylini et al., 2009a; Kulasegaran-
Shylini et al., 2009b), we expected to see two classes of mutants
regarding the expression of the antigen, with a higher subgenomic
transcription driven by the G3 5′ UTR. Analysis of antigen produc-
tion in vivo after injection of replicons delivered as transpackaged
VRP showed an expression pattern that seemed to be regulated by
the predicted folding, with the replicons carrying the G3-like
folding expressing more SEAP in vivo, independently of the
nucleotide sequence at position 3.
Analysis of the effect of these mutations on the replicon’s
ability to induce IFN response when delivered as VRP in IFN-
competent cells showed an interesting pattern. It has widely been
described that the host nucleic acid sensing machinery that
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double strand RNAs, which activate the RNA helicase RIG-I to
initiate expression of IFN α/β (reviewed in Ryman and Klimstra,
2008). Among the panel of mutants we tested, the G3A-A30C had
both the G3A sequence and the TC-83 like predicted folding on the
() RNA strand and was able to induce higher level of IFN, with
respect to the G3 control. This phenotype, similar to the G3A one,
could be explained by the presence in the predicted secondary
structure on the () RNA strand of a dsRNA stem longer than the
one predicted in G3 wt genome and of a smaller terminal loop.
A further conﬁrmation of the role of the secondary structure on
IFN activation came from the analysis of the G3A-C24U mutant.
This 5′ UTR sequence which has been previously described
(Kulasegaran-Shylini et al., 2009a), is characterized by the TC-83-
like G3A mutation and by a predicted stem-loop structure that is
identical to the G3 5′ UTR on both the (+) and () RNA strands. In
our IFN induction assay the VEEV/SINV replicon carrying the
mutated G3A-C24U 5′ UTR was similar to the G3 5′ UTR in terms
of eliciting IFN secretion from infected cells.
The precise effect of IFN activation on immunogenicity of
alphavirus based vaccines is difﬁcult to predict, since IFN induction
could have either a beneﬁcial or a detrimental effect on the
development of the antigen-speciﬁc immune response. The intrin-
sic adjuvant activity of the replicating RNA in the infected cells,
through the recognition by the nucleic acid-sensing machinery,
may potentiate antigen-speciﬁc adaptive immune responses via
IFN induction. A speciﬁc role for type I IFN signaling in alphavirus-
induced adaptive immunity has previously been established as it
has been shown that the activation of B and T lymphocytes is
signiﬁcantly impaired in IFN α/β receptor knock-out mice (Alshariﬁ
et al., 2005). Additional studies performed by Leitner and co-
workers suggested that the ability of replicase-based vaccines to
break immunological tolerance was dependent upon a single
interferon stimulated gene involved in the viral dsRNA response,
RNaseL (Leitner et al., 2003). These early studies are consistent
with more recent studies demonstrating that alphavirus replicon-
based vaccines induce IFN and can adjuvant co-delivered antigens
(Hidmark et al., 2006; Thompson et al., 2008b).
On the other hand, early type I IFN activation could lead to
inhibition of RNA replication and to a reduction of antigen
expression. In particular, there are reports that alphavirus vector-
expressed antigen levels are increased in animals lacking a func-
tional IFN receptor (Leitner et al., 2006; Ryman et al., 2002),
suggesting that, in wt mice, autocrine and paracrine IFN signaling
limit VRP antigen expression.
In our study, the differences in IFN induction measured in vitro
among the replicons carrying different 5′ UTR sequences did not
produce dramatic differences in the immunogenicity of the tested
replicons. However the replicon which induced the highest
amount of IFN in our in vitro system, G3A-A30C, appeared less
potent in vivo than other replicons, suggesting that the IFN
response it generated was detrimental to induction of an antibody
response to its encoded antigen.
To further investigate this detrimental effect of IFN induction
on replicon potency in vivo, we engineered the genome of our
replicon to increase its ability to induce an IFN response. To this
end, we targeted the cleavage site between nsP1 and nsP2 coding
regions. Based on reports from two distantly related alphaviruses,
the AR86 strain of Sindbis and Ross River virus showing that
mutations in this region resulted in enhanced type I IFN induction,
loss of STAT1 inhibition and IRF-3 activation in comparison to the
wt viruses (Cruz et al., 2010; Heise et al., 2003), we elected to
mutate the alanine 533 with an isoleucine in the VEEV/SINV nsP1/
nsP2 cleavage site. This mutation led to increased IFN production
in vitro, conﬁrming the role in IFN modulation of the nsP1/nsP2
cleavage site in VEEV as well. In vivo, the replicon with thismutation was poorly immunogenic, but since it also produced less
antigen in vitro and marker gene in vivo, it is difﬁcult to ascribe its
poorer potency to antigen production or IFN induction.
The viral determinants and the mechanisms controlling the
balance between the adjuvant and the detrimental effect of type I
IFN on alphavirus replicons immunogenicity are still not clear. Our
ﬁndings are consistent with the hypothesis that a balanced, but
not overwhelming IFN response has positive effects on vaccine
outcome. The precise mechanism used by VEEV to modulate host
response to the infection needs to be better understood to enable
the deﬁnition of the factors involved in virus-induced immunity as
well as the design of new strategies to increase the efﬁcacy of VRP
as vaccine vectors.Materials and methods
Cell line propagation and infection
BHK-V cells were maintained in Dulbecco minimum essential
medium (DMEM) supplemented with 10% fetal calf serum (FCS),
L-glutamine, and penicillin–streptomycin at 37 1C with 5% CO2.
Mouse ﬁbroblast L929 were maintained in DMEM supplemented
with 10% fetal calf serum (FCS), L-glutamine, and penicillin–
streptomycin at 37 1C with 5% CO2. Cell monolayers of approxi-
mately 80% conﬂuence were infected with replicon particles with
an MOI of 1 in DMEM containing 1% FCS at 37 1C and then
analyzed 24 h after the beginning of infection. For each replicon
to be analyzed, cells were infected in triplicate and in three
different experiments.
Plasmid constructs
The initial replicon genome was the NVD VEEV/SINV chimeric
replicon that comprises a VEE-based genome containing a SINV
packaging signal and SINV 3′ end (Perri et al., 2003). This replicon
was modiﬁed by replacing the SP6 promoter with the T7 DNA
polymerase promoter and by cloning the gene of interest under
the control of the 26S subgenomic promoter. The poly(A) sequence
was followed by a hepatitis delta virus ribozyme (Dubensky et al.,
1996; Perri et al., 2003), followed by a PmeI restriction site,
required for the linearization of the plasmid before an in vitro
transcription reaction. The resulting replicon is indicated as G3 in
the text and it is the replicon used as backbone to test the selected
modiﬁcations. G3A replicon differed from G3 by one nucleotide in
position 3 (G3A), which was speciﬁc for the VEEV TC-83 5′ UTR,
and by one nucleotide in position 1696 (C1696A), that was speciﬁc
for the VEEV TC-83 nsP2 (Kinney et al., 1993). The 5′ UTR mutants
were obtained by standard PCR-based mutagenesis of the G3 or
G3A replicon using the QuikChange II XL Site-Directed Mutagen-
esis Kit, according to the manufacturer′s instructions (Agilent
Technologies). A30G, A30C and C24U derived from the G3 repli-
con, while G3A-A30G, G3A-A30C and G3A-C24U derived from the
G3A replicon.
G3A-A533I, G3A-A533V and G3A-A533T were cloned from G3A
by standard PCR-based mutagenesis of nucleotide corresponding
to amino acid in position 533 of VEEV. All the modiﬁcations were
tested in the context of SEAP or RSV-F expressing replicons. RSV-F
cDNA encoded for the truncated fusion peptide deleted form of the
F antigen of RSV. The cDNA derives from wt F of RSV strain A2, a
prototypic laboratory subgroup A strain isolated in 1961 from an
infant with bronchiolitis. The RSV-F cDNA used in this study differs
from wt F of the A2 strain because of deletion of the N-terminal
nine amino acids of the fusion peptide (amino acids 137–145 of
the wt F sequence) and of the transmembrane and cytoplasmic tail
regions (amino acids 524–574 of the wt sequence).
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Prior to transcription, the VEEV/SINV genome-coding plasmids
were linearized by PmeI. PmeI-linearized replicons were used
for in vitro transcription reactions. RNAs were synthesized by T7
RNA polymerase in the presence of nucleoside-5′-triphosphates
(NTPs), under the conditions recommended by the manufacturer
(Ambion′s MegaScript Kit). Unincorporated nucleotides were removed
by Lithium Chloride precipitation and the 7-methyguanylate cap
structure (Cap 0) was added to the in vitro transcribed RNA using
the Vaccinia Virus Capping Enzyme under the conditions recom-
mended by the manufacturer (CellScript). The capped RNAs were
puriﬁed by Lithium Chloride precipitation. The yield and integrity of
the transcripts were monitored by gel electrophoresis under non-
denaturing conditions, followed by analysis of the RNA concentration
by OD260 of a diluted aliquot of the reaction.
Production of alphavirus replicon particles
Virus replicon particles (VRP) were generated by co-
electroporation in BHK-V cells of in vitro-transcribed RNAs, corre-
sponding to a replicon and two defective helpers, one expressing
capsid protein and the other expressing envelope glycoproteins
(Perri et al., 2003). Supernatants were harvested 16 h laters,
centrifuged for 10 minutes at 1500 RPM and frozen at 80 1C in
small aliquots. To produce VRP for the in vivo studies, super-
natants collected from electroporated cells were pelleted through
a 20% (w/v) sucrose/phosphate-buffered saline (PBS) cushion at
30,000 RPM by ultracentrifugation (2 h) to purify viral stocks.
Puriﬁed VRP were concentrated on 100 kDa Amicon Ultra-15
Centrifugal Filter Units (Millipore), in accordance with the manu-
facturer′s instructions and 0.1 ml aliquots were frozen at 80 1C.
Replicon particle titers were determined by intracellular staining
of the expressed antigen and of RNA replication following over-
night infection of BHK-V cells with serial dilutions of particles.
Infected cells with VRP expressing RSV-F antigen were permeabi-
lized and ﬁxed by using acetone-methanol 1:1 and then stained
with the antibodies recognizing RSV-F protein (mouse monoclonal
anti-RSV-F antibody, ProSci Incorporated used at 0.1 mg/ml ﬁnal
concentration) or dsRNA intermediates (J2 mouse monoclonal
antibody, English & Scientiﬁc Consulting used at 0.5 mg/ml ﬁnal
concentration). A peroxidase mouse secondary antibody (Jackson
Immunoresearch HRP goat anti mouse IgG (H+L)) followed by
substrate incubation (KPL TrueBlue™) was used to detect the
positive cells and calculate the VRP titers. The titers of SEAP-
expressing VRP were determined by dsRNA staining as described
above and by SEAP protein expression staining. To detect SEAP
positive cells, infected cells were treated with Brefeldin A (Becton
Dickinson) at 1.0 μg/ml ﬁnal concentration for 2 h at 37 1C, ﬁxed
with paraformaldehyde 4% (w/v) in PBS, permeabilized with 0.2%
Triton-X100 in PBS and washed with alkaline phosphatase staining
buffer (Tris 100 mM, pH 9.5, NaCl 100 mM, MgCl2 20 mM). Cells
were incubated overnight with the staining solution (0.1 mg/ml
5-bromo-4-chloro-3-indolyl phosphate, disodium salt (Sigma),
0.5 mg/ml Nitro Blue tetrazolium (Sigma) in alkaline phosphatase
staining buffer) and the reaction was stopped with water. The
number of SEAP expressing cells was counted and the titer
determined.
RNA transfections
The speciﬁc infectivity of in vitro-transcribed, capped replicons
was measured by RNA transfection (serial dilutions starting from an
RNA amount corresponding to 1011 copies/well) into BHK-V cells
in 96-well plates by using Lipofectamine 2000 (Invitrogen) and
Opti-MEM medium (Invitrogen) according to the manufacturer′srecommendations. The transfection mixture was removed after
12 h of incubation and was replaced with DMEM plus 10% FBS. Cells
were analyzed at different times after transfection. For each replicon
to be analyzed, cells were transfected in triplicate and in two
different experiments.
Flow cytometry
To determine the relative RSV-F expression, the viral RNA
replication, and the number of positive cells, VRP or mock infected
BHK-V and L929 cells were analyzed by ﬂow cytometry. Cells
infected with RSV-F expressing VRP were double stained with the
antibodies speciﬁc for RSV-F protein (mouse monoclonal anti-RSV-
F antibody, ProSci Incorporated) and for dsRNA intermediates (J2
mouse monoclonal antibody, English & Scientiﬁc Consulting),
while cells infected with SEAP expressing VRP were stained with
the dsRNA speciﬁc antibody. Brieﬂy, 24 h after the beginning of
infection, mock and VRP infected cells were rinsed and dry
trypsinized and divided into aliquots in parallel groups for stain-
ing. Each aliquot was incubated in staining buffer (0.25% BSA, 0.2%
NaN3 in PBS), permeabilized and ﬁxed by using a Cytoﬁx/Cyto-
perm kit (Becton Dickinson). The samples were stained with the
primary antibody, previously conjugated with a ﬂuorescent Fab
fragment with the Zenon Mouse IgG Labeling Kit (Invitrogen),
according to the manufacturer′s recommendations. Parallel cell
aliquots were left unstained. Stained and unstained cells were
washed and analyzed on a BD Biosciences LSR II ﬂow cytometer.
FlowJo software (Tree Star) was used to analyze the acquired data.
Analysis of protein synthesis
Supernatants from infected cells were used to assess the
amount of secreted antigen by a chemiluminescent assay (SEAP)
or ELISA (RSV-F) 24 h after infection.
The levels of secreted SEAP were measured using the Tropix
Phospha-Light System Kit according to the manufacturer′s instruc-
tions (Applied BioSystems) in the presence of a standard curve for
protein quantiﬁcation.
To determine the concentration of RSV-F protein secreted by
the infected cells a capture ELISA was performed. Plates coated
with 0.06 μg/well of monoclonal RSV-F capture antibody (Maine
Biotech) were incubated with serial dilutions of supernatants or of
a puriﬁed RSV-F protein used to create a standard curve. Bound
protein was detected with a detection monoclonal antibody to
RSV-F, previously conjugated with HRP (Maine Biotech), and
followed by substrate incubation and luminometer reading at
OD450 nm.
The antigen expression levels measured in the supernatant of
in vitro infected cells were normalized for the number of positive
cells, as determined by cytoﬂuorimetric analysis or SEAP protein
expression staining. Results are reported as pg/positive cell, unless
otherwise mentioned. Each sample was tested in triplicate and the
shown data are the result of three different experiments.
Type I IFN assay
The levels of murine IFN-α/β in the supernatant from infected
L929 cell cultures were measured 24 h post-infection, by using the
Mouse Interferon Beta ELISA Kit from PBL Biomedical Laboratories,
under the conditions recommended by the manufacturer. The
measured levels of IFN-β were normalized for the number of
positive cells, as determined by cytoﬂuorimetric analysis. Results
are reported as fg/positive cell, unless otherwise mentioned.
Each sample was tested in triplicate and the shown data are the
result of three different experiments.
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Six to eight weeks old BALB/c mice were obtained from Charles
River Laboratories, and were housed under speciﬁc pathogen-free
conditions, and experiments were approved and performed
according to Novartis Institutional Animal Care and Use Commit-
tee guidelines.
To measure in vivo protein expression driven by the different
replicons, mice (ﬁve per group) were injected with SEAP-
expressing VRPs at 106 IU/mouse (administered intramuscularly
50 μl in each hind leg for mice) on day 0 and sera were collected at
1, 3, 7, and 14 days post-injection. SEAP expression was measured
using the Tropix Phospha-Light System kit according to the
manufacturer′s instructions (Applied BioSystems) in duplicate
wells for each mouse at each time point. Average of the two wells
was considered for each mouse and average of 5 mice was
considered for each time point in the analysis.
Animals were immunized with the indicated RSV-F expressing
vaccines on days 0 and 21. Immunizations were performed
intramuscularly in 100 μl total volume (administered 50 μl in each
hind leg for mice). Serum was collected for antibody analysis
3 weeks after the 1st vaccination (3wp1) and 2 weeks after the
2nd vaccination (2wp2). Mouse spleens were collected at the time
of sacriﬁce (2wp2) for T cell analysis. Endpoint immunogenicity
assays include: ELISA to determine mouse F-speciﬁc serum IgG
titers, intracellular cytokine staining and ﬂow cytometry to deter-
mine F-speciﬁc splenic T cell responses in mice.
Both for SEAP expression and RSV-F immunogenicity in vivo
evaluation, the controls (G3 or G3A) and the described modiﬁed
replicons were tested side by side in the same animal study.
ELISA for F-speciﬁc serum antibody
RSV-F-speciﬁc IgG titers were determined by ELISA according
to the methods described in Geall et al. (2012).
Intracellular cytokines immunoﬂuorescence assay
The ﬁve spleens in each group of mice were pooled, and single
cell-suspensions were prepared. Two antigen-stimulated cultures
and two unstimulated cultures were established for each splenocyte
pool. Antigen-stimulated cultures contained 1106 splenocytes,
RSV-F peptides representing amino acid sequences 85–93, 249–258
(each at 1 mM), RSV-F peptides representing amino acid sequences
51–66, 164–178, and 309–323 (each at 5 mM), anti-CD28 mAb, and
brefeldin A (BD Biosciences). Unstimulated cultures did not contain
RSV-F peptides, but were otherwise identical to the stimulated
cultures. Cells were cultured, stained with antibodies speciﬁc to
CD8 and CD4, ﬁxed and permeabilized, stained with antibodies
speciﬁc to IFNγ, TNFα, IL2, and IL5, and analyzed according to the
methods described in Geall et al. (2012). The net (%) F-speciﬁc T cell
response was calculated as the difference between the percent
cytokine-positive cells in the stimulated cultures and the percent
cytokine positive cells in the unstimulated cultures.
Statistical Analyses
Statistical analysis (paired 2-tailed t-test, Kruskal–Wallis test
and Dunn′s post test) was performed using Prism 5 software
(GraphPad).
Computer analysis of the RNA secondary structures
The optimal secondary structures of the RNAs were predicted
by using the energy minimization program M-Fold (Jaeger et al.,
1989).Acknowledgments
We are grateful to Armin Hekele for technical support in the
replicon cloning; to Amanda McCann for her assistance in produ-
cing the VRPs for these studies; to Melissa Sackal for coordinating
the animal studies; and to Tina Scalzo for conducting immunolo-
gical assays in the RSV-F immunogenicity studies.References
Alshariﬁ, M., Lobigs, M., Regner, M., Lee, E., Koskinen, A., Mullbacher, A., 2005. Type
I interferons trigger systemic, partial lymphocyte activation in response to viral
infection. J. Immunol. 175, 4635–4640.
Atkins, G.J., Fleeton, M.N., Sheahan, B.J., 2008. Therapeutic and prophylactic
applications of alphavirus vectors. Expert Rev. Mol. Med. 10, e33.
Bernstein, D.I., Reap, E.A., Katen, K., Watson, A., Smith, K., Norberg, P., Olmsted, R.A.,
Hoeper, A., Morris, J., Negri, S., Maughan, M.F., Chulay, J.D., 2009. Randomized,
double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalo-
virus in CMV seronegative adult volunteers. Vaccine 28, 484–493.
Cruz, C.C., Suthar, M.S., Montgomery, S.A., Shabman, R., Simmons, J., Johnston, R.E.,
Morrison, T.E., Heise, M.T., 2010. Modulation of type I IFN induction by a
virulence determinant within the alphavirus nsP1 protein. Virology 399, 1–10.
Dubensky Jr., T.W., Driver, D.A., Polo, J.M., Belli, B.A., Latham, E.M., Ibanez, C.E.,
Chada, S., Brumm, D., Banks, T.A., Mento, S.J., Jolly, D.J., Chang, S.M., 1996.
Sindbis virus DNA-based expression vectors: utility for in vitro and in vivo gene
transfer. J. Virol. 70, 508–519.
Fink, K., Lang, K.S., Manjarrez-Orduno, N., Junt, T., Senn, B.M., Holdener, M., Akira, S.,
Zinkernagel, R.M., Hengartner, H., 2006. Early type I interferon-mediated
signals on B cells speciﬁcally enhance antiviral humoral responses. Eur. J.
Immunol. 36, 2094–2105.
Frolov, I., Hardy, R., Rice, C.M., 2001. Cis-acting RNA elements at the 5’ end of
Sindbis virus genome RNA regulate minus- and plus-strand RNA synthesis. RNA
7, 1638–1651.
Gardner, J.P., Frolov, I., Perri, S., Ji, Y., MacKichan, M.L., zur Megede, J., Chen, M., Belli,
B.A., Driver, D.A., Sherrill, S., Greer, C.E., Otten, G.R., Barnett, S.W., Liu, M.A.,
Dubensky, T.W., Polo, J.M., 2000. Infection of human dendritic cells by a sindbis
virus replicon vector is determined by a single amino acid substitution in the E2
glycoprotein. J. Virol. 74, 11849–11857.
Geall, A.J., Verma, A., Otten, G.R., Shaw, C.A., Hekele, A., Banerjee, K., Cu, Y., Beard, C.
W., Brito, L.A., Krucker, T., O’Hagan, D.T., Singh, M., Mason, P.W., Valiante, N.M.,
Dormitzer, P.R., Barnett, S.W., Rappuoli, R., Ulmer, J.B., Mandl, C.W., 2012.
Nonviral delivery of self-amplifying RNA vaccines. Proc. Natl. Acad. Sci. U. S. A.
109, 14604–14609.
Gitlin, L., Barchet, W., Gilﬁllan, S., Cella, M., Beutler, B., Flavell, R.A., Diamond, M.S.,
Colonna, M., 2006. Essential role of mda-5 in type I IFN responses to
polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus.
Proceedings of the National Academy of Sciences of the United States of
America 103, 8459–8464.
Gorchakov, R., Hardy, R., Rice, C.M., Frolov, I., 2003. Selection of Functional 5’ cis-
Acting Elements Promoting Efﬁcient Sindbis Virus Genome Replication. J. Virol.
78, 61–75.
Heise, M.T., White, L.J., Simpson, D.A., Leonard, C., Bernard, K.A., Meeker, R.B.,
Johnston, R.E., 2003. An Attenuating Mutation in nsP1 of the Sindbis-Group
Virus S.A.AR86 Accelerates Nonstructural Protein Processing and Up-Regulates
Viral 26S RNA Synthesis. J. Virol. 77, 1149–1156.
Hidmark, A.S., Nordstrom, E.K., Dosenovic, P., Forsell, M.N., Liljestrom, P., Karlsson
Hedestam, G.B., 2006. Humoral responses against coimmunized protein anti-
gen but not against alphavirus-encoded antigens require alpha/beta interferon
signaling. J. Virol. 80, 7100–7110.
Jaeger, J.A., Turner, D.H., Zuker, M., 1989. Improved predictions of secondary
structures for RNA. Proceedings of the National Academy of Sciences of the
United States of America 86, 7706–7710.
Kinney, R.M., Chang, G.J., Tsuchiya, K.R., Sneider, J.M., Roehrig, J.T., Woodward, T.M.,
Trent, D.W., 1993. Attenuation of Venezuelan equine encephalitis virus strain
TC-83 is encoded by the 5’-noncoding region and the E2 envelope glycoprotein.
J. Virol. 67, 1269–1277.
Kulasegaran-Shylini, R., Atasheva, S., Gorenstein, D.G., Frolov, I., 2009a. Structural
and functional elements of the promoter encoded by the 5’ untranslated region
of the Venezuelan equine encephalitis virus genome. J. Virol. 83, 8327–8339.
Kulasegaran-Shylini, R., Thiviyanathan, V., Gorenstein, D.G., Frolov, I., 2009b. The
5’UTR-speciﬁc mutation in VEEV TC-83 genome has a strong effect on RNA
replication and subgenomic RNA synthesis, but not on translation of the
encoded proteins. Virology 387, 211–221.
Leitner, W.W., Bergmann-Leitner, E.S., Hwang, L.N., Restifo, N.P., 2006. Type I
Interferons are essential for the efﬁcacy of replicase-based DNA vaccines.
Vaccine 24, 5110–5118.
Leitner, W.W., Hwang, L.N., deVeer, M.J., Zhou, A., Silverman, R.H., Williams, B.R.,
Dubensky, T.W., Ying, H., Restifo, N.P., 2003. Alphavirus-based DNA vaccine
breaks immunological tolerance by activating innate antiviral pathways. Nat.
Med. 9, 33–39.
G. Maruggi et al. / Virology 447 (2013) 254–264264Lemm, J.A., Rice, C.M., 1993. Roles of nonstructural polyproteins and cleavage
products in regulating Sindbis virus RNA replication and transcription. J. Virol.
67, 1916–1926.
Lemm, J.A., Rumenapf, T., Strauss, E.G., Strauss, J.H., Rice, C.M., 1994. Polypeptide
requirements for assembly of functional Sindbis virus replication complexes: a
model for the temporal regulation of minus- and plus-strand RNA synthesis.
EMBO J. 13, 2925–2934.
Liljestrom, P., Garoff, H., 1991. A new generation of animal cell expression vectors
based on the Semliki Forest virus replicon. Biotechnology (N Y) 9, 1356–1361.
MacDonald, G.H., Johnston, R.E., 2000. Role of dendritic cell targeting in Venezuelan
equine encephalitis virus pathogenesis. J. Virol. 74, 914–922.
Nishimoto, K.P., Laust, A.K., Wang, K., Kamrud, K.I., Hubby, B., Smith, J.F., Nelson, E.L.,
2007. Restricted and selective tropism of a Venezuelan equine encephalitis
virus-derived replicon vector for human dendritic cells. Viral Immunol. 20,
88–104.
Perri, S., Greer, C.E., Thudium, K., Doe, B., Legg, H., Liu, H., Romero, R.E., Tang, Z., Bin,
Q., Dubensky, T.W., Vajdy, M., Otten, G.R., Polo, J.M., 2003. An Alphavirus
Replicon Particle Chimera Derived from Venezuelan Equine Encephalitis and
Sindbis Viruses Is a Potent Gene-Based Vaccine Delivery Vector. J. Virol. 77,
10394–10403.
Pichlmair, A., Schulz, O., Tan, C.P., Rehwinkel, J., Kato, H., Takeuchi, O., Akira, S., Way,
M., Schiavo, G., Reis e Sousa, C., 2009. Activation of MDA5 requires higher-order
RNA structures generated during virus infection. J. Virol. 83, 10761–10769.
Pushko, P., Parker, M., Ludwig, G.V., Davis, N.L., Johnston, R.E., Smith, J.F., 1997.
Replicon-helper systems from attenuated Venezuelan equine encephalitis
virus: expression of heterologous genes in vitro and immunization against
heterologous pathogens in vivo. Virology 239, 389–401.
Rayner, J.O., Dryga, S.A., Kamrud, K.I., 2002. Alphavirus vectors and vaccination. J.
Virol. 12, 279–296.Ryman, K.D., Klimstra, W.B., 2008. Host responses to alphavirus infection. Immunol.
Rev. 225, 27–45.
Ryman, K.D., White, L.J., Johnston, R.E., Klimstra, W.B., 2002. Effects of PKR/RNase L-
dependent and alternative antiviral pathways on alphavirus replication and
pathogenesis. Viral Immunol. 15, 53–76.
Simmons, J.D., Wollish, A.C., Heise, M.T., 2010. A determinant of Sindbis virus
neurovirulence enables efﬁcient disruption of Jak/STAT signaling. J. Virol. 84,
11429–11439.
Strauss, J.H., Strauss, E.G., 1994. The alphaviruses: gene expression, replication, and
evolution. Microbiol. Rev. 58, 491–562.
Thompson, J.M., Whitmore, A.C., Konopka, J.L., Collier, M.L., Richmond, E.M., Davis,
N.L., Staats, H.F., Johnston, R.E., 2006. Mucosal and systemic adjuvant activity of
alphavirus replicon particles. Proc. Natl. Acad. Sci. U. S. A. 103, 3722–3727.
Thompson, J.M., Whitmore, A.C., Staats, H.F., Johnston, R., 2008a. The contribution
of type I interferon signaling to immunity induced by alphavirus replicon
vaccines. Vaccine 26, 4998–5003.
Thompson, J.M., Whitmore, A.C., Staats, H.F., Johnston, R.E., 2008b. Alphavirus
replicon particles acting as adjuvants promote CD8+ T cell responses to co-
delivered antigen. Vaccine 26, 4267–4275.
Ulmer, J.B., Mason, P.W., Geall, A., Mandl, C.W., 2012. RNA-based vaccines. Vaccine
30, 4414–4418.
van den Broek, M.F., Muller, U., Huang, S., Aguet, M., Zinkernagel, R.M., 1995.
Antiviral defense in mice lacking both alpha/beta and gamma interferon
receptors. J. Virol. 69, 4792–4796.
White, L.J., Wang, J.G., Davis, N.L., Johnston, R.E., 2001. Role of alpha/beta interferon
in Venezuelan equine encephalitis virus pathogenesis: effect of an attenuating
mutation in the 5’ untranslated region. J. Virol. 75, 3706–3718.
Xiong, C., Levis, R., Shen, P., Schlesinger, S., Rice, C.M., Huang, H.V., 1989. Sindbis
virus: an efﬁcient, broad host range vector for gene expression in animal cells.
Science 243, 1188–1191.
